Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -720K | 0 | -457K | -60K | -66K |
| Operating Income | -3M | -2K | -2M | -3M | -11M |
| EBITDA | -3M | -2K | -2M | -3M | -11M |
| Net Income | -3M | -3M | -3M | -2M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.222
+0.00% today
1Y Change
-33.00%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sona Nanotech Inc. (SNANF) is a Healthcare stock with a market cap of $40.00M and listed on OTC. The stock last traded around $0.22 and down 33.0% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -7.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -7.4%, free cash flow -0.1% with operating margin 0.0% and ROIC -1878.2%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SNANF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNANF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SNANF Max Drawdown
-61.71%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SNANF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$10.4M
-339.1% YoY
Free Cash Flow
-$3.8M
-111.2% YoY
Revenue Growth
+0.0%
EPS Growth
-7.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -720K | 0 | -457K | -60K | -66K |
| Operating Income | -3M | -2K | -2M | -3M | -11M |
| EBITDA | -3M | -2K | -2M | -3M | -11M |
| Net Income | -3M | -3M | -3M | -2M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 122K | 2M | 109K | 155K | 1M |
| Total Assets | 1M | 4M | 3M | 521K | 2M |
| Total Liabilities | 1M | 1M | 2M | 1M | 3M |
| Shareholder Equity | -39K | 3M | 1M | -508K | -1M |
| Total Debt | 308K | 395K | 528K | 608K | 1M |
| Net Debt | 186K | -1M | 418K | 453K | 153K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
-111.2% YoY
Capital Expenditures
0
Free Cash Flow
4M
-111.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1043.0%
Debt / Equity
-1.96x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.